| Literature DB >> 28821850 |
Miaomiao Jiang1, Qiuying Wang1, Jingrui Chen1, Yanan Wang2, Guanwei Fan3,4, Yan Zhu5.
Abstract
Metabonomics/metabolomics is a rapid technology for comprehensive profiling of small molecule metabolites in cells, tissues, or whole organisms, the application of which has led to understanding pathophysiologic mechanisms of cardiometabolic diseases, defining predictive biomarkers for those diseases, and also assessing the efficacious effects of incident drugs. In this study, proton nuclear magnetic resonance (NMR)-based metabonomics was employed to identify the metabolic changes in rat plasma caused by myocardial ischemia-reperfusion injury (MIRI), and to compare the metabolic regulatory differences between traditional Chinese medicine Wenxin Keli (WXKL) and Western medicine verapamil. The results revealed that energy-substrate metabolism were significantly disturbed by ischemia-reperfusion (I/R) in myocardium and bulk of the key metabolites could be further modulated by verapamil and/or WXKL. Lipid metabolism and amino acid transamination occurred mainly following the treatment of verapamil, whereas glucose oxidation and BCAA degradation were prominently ameliorated by WXKL to content the energy demands of heart. Moreover, both WXKL and verapamil improved the secretions of taurine and ketone bodies to overcome the oxidative stress and the shortage of energy sources induced by ischemia-reperfusion.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28821850 PMCID: PMC5562700 DOI: 10.1038/s41598-017-09547-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effects of WXKL and verapamil on rat cardiac function. Quantitative assessment of dilation and systolic function as (A) left ventricular ejection fraction (LVEF), (B) left ventricular fractional shortening (LVFS), (C) left ventricular end-systolic dimension (LVIDs), (D) left ventricular systolic volume (LV Vols), (E) left ventricular end-systolic anterior wall (LVAWs), (F) ratio of E-wave to A-wave (E/A), (G) aorta velocity time integral mean velocity (AoV VTI), and (H) aortic valve peak velocity (Peak vel). Data are expressed as means ± S.D.; *p < 0.05, **p < 0.01 versus sham group; # p < 0.05, ## p < 0.01 versus model group.
Figure 2Effects of WXKL and verapamil on hemodynamics post I/R injury. Quantitative hemodynamic assessment was carried out on the left ventricle through right carotid artery to evaluate the role of WXKL or verapamil for I/R injury. (A) heart rate (HR), (B) left ventricular systolic pressure (LVSP), (C) left ventricular development pressure (LVDP), (D) left ventricular end diastolic pressure (LVEDP), (E) left ventricular maximum upstroke velocity (+dp/dt max), and (F) left ventricular maximum descent velocity (−dp/dt max). Data are expressed as means ± S.D.; **p < 0.01 compared with sham group; # p < 0.05, ## p < 0.01 compared with model group.
Figure 3Typical standard 1H-NMR spectra of plasma samples collected from sham, MIRI, Ver and WXKL rats. The keys for metabolites are given in Table 1.
1H-NMR data for metabolites identified from the rat serum samples.
| Peak | Metabolites |
|
|---|---|---|
| 1 | lipids | 0.86 (br. s), 1.26 (m), 2.77 (m), 5.28 (m) |
| 2 | leucine | 0.92 (d), 0.93 (d), 1.70 (m) |
| 3 | isoleucine | 0.94 (t), 0.99 (d), 3.66 (d) |
| 4 | valine | 0.97 (d), 1.04 (d), 3.60 (d) |
| 5 | 3-hydroxybutyrate | 1.18 (d), 2.28 (dd), 2.39 (dd), 4.14 (m) |
| 6 | lactate | 1.31 (d), 4.11 (q) |
| 7 | alanine | 1.47 (d), 3.76 (m) |
| 8 | acetate | 1.91 (s) |
| 9 | N-acetyl glycoprotein | 2.02 (br. s) |
| 10 | O-acetyl glycoprotein | 2.12 (br. s) |
| 11 | acetone | 2.21 (s) |
| 12 | acetoacetate | 2.26 (s) |
| 13 | pyruvate | 2.35 (s) |
| 14 | glutamate | 2.12 (m), 2.04 (m), 2.34 (m), 3.76 (m) |
| 15 | glutamine | 2.13 (m), 2.44 (m), 3.77 (m) |
| 16 | malate | 2.66 (dd), 2.37 (dd), 4.23 (br. d) |
| 17 | creatine phosphate | 3.03 (s), 3.93 (s) |
| 18 | choline | 3.19 (s) |
| 19 | trimethylamine N-oxide | 3.25 (s) |
| 20 | taurine | 3.25 (t), 3.40 (t) |
| 21 | methanol | 3.34 (s) |
| 22 | glycine | 3.55 (s) |
| 23 | threonine | 3.58 (d), 1.32 (d), 4.25 (m) |
| 24 | glycerol | 3.64 (dd), 3.55 (dd), 3.77 (m) |
| 25 | serine | 3.93 (dd), 3.98 (dd) |
| 26 | glucose | 5.22 (d), 4.64 (d), 3.89 (dd), 3.83 (m), 3.72 (m), 3.53 (dd), 3.46 (m), 3.40 (t), 3.24 (dd) |
| 27 | tyrosine | 6.89 (d), 7.18 (d) |
| 28 | phenylalanine | 7.31 (m), 7.37 (m), 7.41 (m) |
| 29 | formate | 8.44 (s) |
aMultiplicity: singlet (s), doublet (d), triplet (t), doublet of doublets (dd), quintet (q), multiplet (m).
Figure 4The score plots and VIP plots between (A,B) sham and MIRI groups, (C,D) MIRI and Ver groups, (E,F) MIRI and WXKL groups. (G) A summary of the differential metabolites extracted in the three comparison cases.
The dominating metabolites extracted by multivariate statistical analysis that discriminated the cases of MIRI vs. Sham, Ver vs. MIRI, and WXKL vs. MIRI.
| Metabolite ( | PLS-DA (VIP value) |
| Fold change |
|---|---|---|---|
|
| |||
| lipids (0.86) | 2.38 | 0.002 | 2.81 |
| lipids (1.26) | 3.21 | 0.001 | 6.38 |
| leucine + isoleucine (0.93) | 1.52 | 0.043 | 1.29 |
| lactate (1.31) | 11.39 | 0.022 | 0.73 |
| lactate (4.11) | 5.02 | 0.024 | 0.74 |
| alanine (1.48) | 2.86 | 0.001 | 0.65 |
| glutamate (2.34) | 2.03 | 0.008 | 0.75 |
|
| |||
| lipids (0.86) | 1.57 | 0.003 | 0.49 |
| lipids (1.26) | 2.03 | 0.005 | 0.36 |
| lactate (1.31) | 12.22 | 0.001 | 1.61 |
| lactate (4.11) | 5.20 | 0.001 | 1.57 |
| alanine (1.48) | 1.44 | 0.021 | 1.31 |
| acetoacetate (2.26) | 2.64 | 0.036 | 0.30 |
| glutamate (2.34) | 1.69 | 0.011 | 1.43 |
| taurine (3.26) | 2.47 | 0.025 | 0.75 |
| taurine (3.43) | 1.18 | 0.043 | 0.78 |
|
| |||
| leucine + isoleucine (0.93) | 1.33 | 0.036 | 0.77 |
| valine (1.04) | 1.72 | 0.035 | 0.47 |
| 3-hydroxybutyrate (1.18) | 4.57 | 0.033 | 0.22 |
| 3-hydroxybutyrate (2.28) | 1.90 | 0.020 | 0.22 |
| acetoacetate (2.26) | 3.52 | 0.012 | 0.18 |
| glutamine (2.13) | 2.70 | 0.012 | 0.79 |
| glutamine (2.44) | 1.37 | 0.026 | 0.65 |
| creatine (3.03) | 2.37 | 0.033 | 0.55 |
| taurine (3.26) | 3.67 | 0.005 | 0.64 |
| taurine (3.43) | 1.60 | 0.007 | 0.75 |
| glucose (5.22) | 3.35 | 0.014 | 1.74 |
Figure 5Visualization of the involved pathway for the differential metabolites. The summarized pathway is based on KEGG database (http://www.kegg.jp/).The metabolites in blue were detected in the NMR spectra whereas those in black failed NMR detection. Box plots showed the normalized relative contents of these differential metabolites in the four treatment groups.
Figure 6A summary of the metabolic responses of MIRI rats treated by WXKL and verapamil.